Advertisement
Baxter
Subscribe to Baxter

The Lead

Baxter Recalls One Lot of Potassium Chloride Injection

September 17, 2014 3:00 pm | News | Comments

Baxter International Inc. announced today it is voluntarily recalling one lot of Potassium Chloride Injection 10mEq per 100mL, product code 2B0826 to the hospital/pharmacy/nurse level. The recall is being initiated due to a labeling error on the shipping cartons in a single lot, which was identified by three customers.

FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency

September 15, 2014 8:31 am | News | Comments

Baxter International and Halozyme Therapeutics announced that the FDA approved Baxter’s...

Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company

September 11, 2014 8:37 am | News | Comments

Baxter International has announced that Baxalta Incorporated will be the name of the new,...

Baxter to Sell Commercial Vaccines Business to Pfizer

July 30, 2014 8:06 am | News | Comments

Baxter International has entered into a definitive agreement to sell its two commercially...

View Sample

FREE Email Newsletter

Baxter Acquires AesRx, LLC, Including Its Investigational Sickle Cell Disease Treatment

July 9, 2014 9:08 am | News | Comments

Baxter International Inc. announces the acquisition of AesRx, LLC, a private U.S. biopharmaceutical company focused on orphan drug targets, including the development and commercialization of Aes-103, an investigational prophylactic treatment for sickle cell disease (SCD).

Baxter to Create Two Separate Global Healthcare Companies

March 27, 2014 8:19 am | News | Comments

Baxter International has announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products.    

Baxter Recalls One Lot of Peritoneal Dialysis Solution

March 6, 2014 11:13 am | News | Comments

The recall is being initiated as a result of complaints of particulate matter, identified as mold, resulting from a leak in the container.                    

Advertisement

Baxter Restructures Agreement with Xenetic Biosciences

January 30, 2014 8:05 am | News | Comments

Baxter International has restructured its ongoing agreement with Xenetic Biosciences, for the development of BAX 826, a recombinant Factor VIII treatment for hemophilia A under investigation to assess its potential to extend the half-life and duration of effectiveness.

Baxter Initiates Nationwide Voluntary Recall of Select Lots of Premix Parenteral Nutrition

January 6, 2014 8:21 am | News | Comments

Baxter International Inc. has initiated a voluntary recall in the United States of two lots of CLINIMIX and one lot of CLINIMIX E Injection parenteral nutrition products to the user level due to complaints of particulate matter found in the products

Cell Therapeutics in $172M Partnership with Baxter

November 18, 2013 8:17 am | News | Comments

Cell Therapeutics and Baxter International announced a partnership on Cell Therapeutics' drug pacritinib, a potential treatment for the bone marrow disease myelofibrosis. Cell Therapeutics said it could get as much as $172 million in payments from Baxter, and the companies will split the profits on U.S. sales if the drug is approved.

Baxter Meets Third Quarter Expectations

October 17, 2013 8:09 am | News | Comments

Baxter International Inc. today posted solid financial results for the third quarter which met expectations as the company further augmented its portfolio with the acquisition of Gambro AB, and continued to advance its new product pipeline by launching new products, achieving multiple regulatory milestones, and establishing new collaborations.

Baxter Initiates Voluntary Recall of Two Lots of Dual Luer Lock Caps

September 20, 2013 7:50 am | News | Comments

Baxter International Inc. has initiated a voluntary recall of two lots of its Dual Luer Lock Caps (Product Code 2C6250, Lots 10043 and 10044) because of the presence of loose particulate matter found in the packaging. Particulate matter entering the fluid path from the Luer Lock Caps may result in thrombotic and embolic events, including: pulmonary embolism, myocardial infarction and stroke.

Advertisement

Baxter Completes $3.9B Acquisition of Gambro

September 6, 2013 8:21 am | News | Comments

Baxter International Inc. has closed on its approximately $3.9 billion acquisition of Swiss dialysis products company Gambro AB. In July the European Union's antitrust authority cleared Baxter's bid for privately held Gambro.   

EU Clears Baxter's $2.76B Bid for Gambro

July 23, 2013 8:23 am | News | Comments

The European Union's antitrust authority has cleared  Baxter's proposed $2.76B takeover bid of Sweden's dialysis products firm Gambro.                   

Baxter Reports Solid Second Quarter Financial Results

July 18, 2013 10:07 am | News | Comments

Baxter International has announced solid financial results for the second quarter, with earnings that exceeded the company’s previously issued guidance, and confirmed its full-year 2013 financial outlook.        

Baxter Says Promising Alzheimer’s Treatment Has Failed In Late-Stage Clinical Trial

May 7, 2013 2:32 pm | by ANDREW POLLACK, New York Times News Service | News | Comments

In yet another setback for the treatment of Alzheimer’s disease, Baxter said that a promising new therapy had failed to halt the mental decline caused by the disease in a late-stage clinical trial. Prospects that the drug might have some effect brightened last year when researchers reported that four patients who had received the maximum dose had gone three years without any decline in several measures of cognition and daily functioning,

Pharma Firm Near Win in Quiet Push for Minnesota Breaks

April 29, 2013 8:18 am | by BRIAN BAKST,Associated Press | News | Comments

In early February, a development agency in Minnesota’s Gov. Mark Dayton's administration made a deal with a giant pharmaceutical company: The state would explore grants and tax breaks that could yield almost 200 high-wage jobs all while keeping Baxter Healthcare Group's name out of the public conversation.

Advertisement

Minnesota Floats $15.4M in Subsidies for Biotech Firm

April 18, 2013 10:13 am | by BRIAN BAKST,Associated Press | News | Comments

State leaders stand ready to commit up to $15.4 million in taxpayer subsidies to a Fortune 500 pharmaceutical company they hope will put an outpost in Minnesota, according to a document made public Wednesday.  After declining to provide details the day before, Gov. Mark Dayton's office released a February letter from the governor and top legislators to a site hunter for Baxter Healthcare Corp.

Baxter Closes Deal for Potential Hemophilia Drug

March 21, 2013 10:09 am | by The Associated Press | News | Comments

  Baxter International Inc. has closed its acquisition of a potential hemophilia treatment from the French drugmaker Ipsen and Inspiration Biopharmaceuticals Inc. in a deal that could be worth more than $180 million. Baxter had said in January it agreed to buy the drug, labeled OBI-1, and related manufacturing operations.

Baxter to Lay Off 400 Workers in Puerto Rico

March 11, 2013 8:03 am | News | Comments

Baxter International Inc. is laying off 400 workers at a pharmaceutical plant in Puerto Rico. The company is one of the largest employers in the central mountain town of Aibonito, where the plant is located. The executive director of the island's Industrial Development Company says the layoffs will be gradual and that the agency will help find jobs for displaced workers.

Baxter Reports Record Sales, Earnings and Cash Flow for Full-Year 2012

January 24, 2013 2:21 am | by Baxter Healthcare | News | Comments

Baxter Provides Financial Outlook For 2013

Baxter Announces Agreement to Acquire Investigational Hemophilia Compound OBI-1 and Related Assets

January 24, 2013 2:21 am | by Baxter Healthcare | News | Comments

DEERFIELD, Ill., January 24, 2013 - Baxter International Inc. (NYSE:BAX) announced today that it has agreed to acquire the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, Inc. as well as certain other OBI-1 related assets, including...

St. Joseph's/Candler Health System in Savannah, Ga. Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service

January 23, 2013 4:22 am | by Baxter Healthcare | News | Comments

CHICAGO, January 23, 2013 - In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, St. Joseph's/Candler Health System in Savannah, Ga. is the recipient of the 2012 Foster G. McGaw Prize for Excellence in Community...

Health System in Savannah, Ga. Recognized for Community Service Commitment with Foster G. McGaw Prize

January 23, 2013 4:21 am | by Baxter Healthcare | News | Comments

After back surgery and an extended stay in the hospital, Savannah, Ga. resident Denet Whitfield found herself out of a job and without a source of income. She couldn't even afford groceries and feared losing her apartment. After reaching out to several government agencies for help, she...

Baxter Helps Expand Treatment Access and Options for End-Stage Kidney Disease Patients

January 10, 2013 5:21 am | by Baxter Healthcare | News | Comments

As the prevalence of end-stage kidney disease continues to rise worldwide, Baxter is helping expand access to life-sustaining treatment options. Teeramanas Tanaekakarapong of Bangkok is one of thousands of patients in Thailand and across Asia Pacific relying on Baxter's peritoneal...

Baxter Announces Phase III Data Evaluating Prophylaxis Treatment of FEIBA NF for Hemophilia Patients with Inhibitors

January 8, 2013 4:21 am | by Baxter Healthcare | News | Comments

DEERFIELD, Ill., JANUARY 8, 2013 - Baxter International Inc. (NYSE:BAX) today announced pivotal Phase III study results evaluating the efficacy and safety of routine prophylaxis compared to on-demand treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated,...

Baxter to Initiate Late-Stage Clinical Trial of BAX 855 for the Treatment of Hemophilia A

January 7, 2013 4:21 am | by Baxter Healthcare | News | Comments

DEERFIELD, Ill., January 7, 2013 - Baxter International Inc. (NYSE:BAX) today announced it has submitted an Investigational New Drug (IND) application for its investigational hemophilia A treatment BAX 855 with the U.S. Food and Drug Administration, following positive results from a Phase...

Aide Takes Plea in Vegas Hepatitis Exposure Case

December 11, 2012 3:11 am | by KEN RITTER,Associated Press | News | Comments

LAS VEGAS (AP) — A former aide at a Las Vegas outpatient clinic where authorities say patients became infected with hepatitis C in 2007 pleaded guilty Monday to felony neglect and other charges and agreed to testify against the former clinic owner.  

Baxter Presents Phase I/III Data Evaluating Safety and Efficacy of BAX 326, An Investigational Recombinant Factor IX for Hemophilia B, Showing More Than 40 Percent of Patients...

December 10, 2012 4:21 am | by Baxter Healthcare | News | Comments

DEERFIELD, Ill., December 10, 2012 - Baxter International Inc. (NYSE:BAX) today announced pivotal Phase I/III study results evaluating the safety and efficacy of BAX 326, an investigational recombinant factor IX (rFIX) protein, for the treatment and prophylaxis of bleeding episodes for...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading